Up-regulated dopamine D1 receptor binding can be detected in vivo following repeated SCH 23390, but not SKF 81297 or 6-hydroxydopamine, treatments

European Journal of Pharmacology

Volumn 459, Issue 2-3, 2003, Pages 195-201

  Schwartz, Robert A ^a,b   Greenwald, Eric R ^a,b   Fletcher, Paul J ^a,c   Houle, Sylvain ^a,c   DaSilva, Jean N ^a,b,c,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Apomorphine; CAMP mediated signaling pathway; PET (positron emission tomography); Receptor supersensitivity; Up regulation; Uptake

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DOPAMINE 1 RECEPTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN INJURY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; FOLLOW UP; IN VIVO STUDY; MALE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0037449476     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02850-9     Document Type: Article

References (38)

1. Boyson S.J., McGonigle P., Molinoff P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
2. Braun A.R., Chase T.N. Behavioural effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. Eur. J. Pharmacol. 147:1988;441-451.
3. Breese G.R., Traylor T.D. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther. 174:1970;413-420.
4. Brownell A.-L., Hantraye P., Wullner U., Hamberg L., Shoup T., Elmaleh D.R., Frim D.M., Madras B.K., Brownell G.L., Rosen B.R., Isacson O. PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp. Neurol. 125:1994;41-51.
5. Cai G., Wang H.-Y., Bhamre S., Friedman E. Enhanced D1 dopamine receptor/G protein coupling in unilateral 6-hydroxydopamine-lesioned rats. Soc. Neurosci. Abst. 24:1998;859.
6. Creese I., Chen A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109:1985;127-128.
7. 11C]SKF 82957: synthesis and in vivo characterization in rats. Nucl. Med. Biol. 26:1999;537-542.
8. Gnanalingham K.K., Hunter A.J., Jenner P., Marsden C.D. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat - relationship to circling behaviour. Biochem. Pharmacol. 49:1995;1185-1193.
9. Graham W.C., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res. 514:1990;93-102.
10. olf in the coupling of dopamine D1 receptor with adenylyl cyclase. J. Neurosci. 13:1993;2237-2248.
11. Hess E.J., Albers L.J., Le H., Creese I. Effects of chronic SCH23390 treatment on the biochemical and behavioural properties of D1 and D2 dopamine receptors: potential behavioural reponses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J. Pharmacol. Exp. Ther. 238:1986;846-854.
12. Hu X.-T., Brooderson R.J., White F.J. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum. Neuroscience. 50:1992;137-147.
13. Hudson J.L., van Horne C.G., Strömberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine- and amphetamine- induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
14. Iwata S.-I., Shimizu T., Nomoto M., Fukuda T. Characteristic upregulation of dopamine D1-receptor in rat striatum after 6-hydroxydopamine treatment. Jpn. J. Pharmacol. 71:1996;255-258.
15. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. Exp. Neurol. 113:1991;277-290.
16. Lappalainen J., Hietala J., Koulu M., Seppälä T., Sjöholm B., Syvälahti E. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J. Pharmacol. Exp. Ther. 252:1990;845-852.
17. Lappalainen J., Hietala J., Pohjalainen T., Syvälahti E. Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur. J. Pharmacol. 210:1992;195-200.
18. Lawler C.P., Gilmore J.H., Watts V.J., Walker Q.D., Southerland S.B., Cook L.L., Mathis C.A., Mailman R.B. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model. Synapse. 21:1995;299-311.
19. Mackay D. Agonist potency and apparent affinity: interpretation using classical and steady-state ternary-complex models. Trends Pharmacol. Sci. 11:1990;17-22.
20. Marcotte E.R., Sullivan R.M., Mishra R.K. Striatal G-proteins: effects of unilateral 6-hydroxydopamine lesions. Neurosci. Lett. 169:1994;195-198.
21. Matsuda H., Hiyama Y., Terasawa K., Watanabe H., Matsumoto K. Enhancement of rotational behaviour induced by repeated administration of SKF38393 in rats with unilateral nigrostriatal 6-OHDA lesions. Pharmacol. Biochem. Behav. 42:1992;213-218.
22. McCreary A.C., Marsden C.A. Cocaine-induced behaviour: dopamine D1 receptor antagonism by SCH 23390 prevents expression of conditioned sensitisation following repeated administration of cocaine. Neuropharmacology. 32:1993;387-391.
23. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
24. Mokrý J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol. Res. 44:1995;143-150.
25. Neisewander J.L., Lucki I., McGonigle P. Behavioural and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
26. Neisewander J.L., Lucki I., McGonigle P. Changes in behavioural sensitivity to SKF-38393 and quinpirole following withdrawal from continuous cocaine administration in rats. Pharmacol. Biochem. Behav. 53:1996;935-942.
27. oα in discrete regions of rat brain. J. Neurochem. 55:1990;1079-1082.
28. Ohara K., Haga K., Berstein G., Haga T., Ichiyama A., Ohara K. The interaction between D-2 dopamine receptors and GTP-binding proteins. Mol. Pharmacol. 33:1988;290-296.
29. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd ed. 1997;Academic Press, San Diego, CA.
30. Pinna A., Morelli M., Drukarch B., Stoof J.C. Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. Eur. J. Pharmacol. 331:1997;23-26.
31. Porceddu M.L., Giorgi O., De Montis G., Mele S., Cocco L., Ongini E., Biggio G. 6-Hydroxydopamine-induced degeneration of nigral dopamine neurons: differential effect on nigral and striatal D-1 dopamine receptors. Life Sci. 41:1987;697-706.
32. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
33. 11C]SCH 23390). Int. J. Rad. Appl. Instrum. Part A. 38:1987;305-306.
34. Rinne J.O., Laihinen A., Någren K., Bergman J., Solin O., Haaparanta M., Ruotsalainen U., Rinne U.K. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J. Neurosci. Res. 27:1990;494-499.
35. Sedvall C.G., Farde L., Hall H., Halldin C., Karlsson P., Brene S., Lindefors N., Persson H., Chipkin R.E., Ehrlich M., Greengard P. Ligand selection for PET studies of D1 dopamine receptors. Relationship between distribution of binding sites and mRNA for DAARPP32 in the human brain. Clin. Neuropharmacol. 15S:1992;466-467.
36. Seeman P., Grigoriadis D. Dopamine receptors in brain and periphery. Neurochem. Int. 10:1987;1-25.
37. Stripling J.S., Ellinwood E.H.J. Sensitization to cocaine following chronic administration in the rat. Ellinwood E.H., Kilbey M.M. Cocaine and Other Stimulants. 1977;327-351 Plenum Press, New York, NY.
38. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93.